The Guangdong-Hong Kong-Macao Greater Bay Area now hosts the world's first full industrial-chain platform for animal-free heparin, launched in Guangming District.
Bloomage Gag Biotech (Shenzhen) Co., Ltd., a subsidiary of global hyaluronic acid leader Bloomage Biotech, has established its base in Guangming. On July 7, a signing ceremony marked agreements between Bloomage Gag, the Guangming District Government, the National Innovation Center for Biomanufacturing, and Xingbo Shenghui Private Equity Venture Capital Fund for project implementation and angel-round financing support.
The partnership aims to leverage Guangming's favorable policies, national innovation resources, and Bloomage's industrial expertise to accelerate the development of this pioneering synthetic biology project.
This initiative represents Bloomage Biotech's strategic expansion beyond hyaluronic acid into synthetic biology, focusing on glycobiology and cell biology. The company's diverse portfolio includes four core segments: bioactive ingredients, pharmaceuticals and medical devices, dermatology, and nutritional science, with consumer brands like BIOHYALUX, QUADHA, Bio-MESO, and MEDREPAIR. Bloomage Gag has made significant breakthroughs in enzymatic heparin synthesis, targeting applications across cosmetics, pharmaceuticals, and medical devices. Heparin plays a crucial role in preventing and treating thrombotic diseases, myocardial infarction, and supporting anticoagulation during cardiovascular surgeries.
As a synthetic biology innovator, Bloomage Gag aims to establish a world-leading heparin industrial chain, using this platform to drive advances in medicine, glycochemical reagents, cosmetics, and medical devices, heralding a new era for the heparin industry.
Following the launch, a roundtable titled “Synthetic Biology Empowering Heparin Industry Transformation” brought together experts from academia, industry, and investment, including: Zhang Xian’en, dean of the Faculty of Synthetic Biology at Shenzhen Universality of Advanced Technology, Guo Xueping, chairman and general manager of Bloomage Gag, Ma Yingfei, chief scientist at the National Innovation Center for Biomanufacturing, Gu Zheyi, founding partner of Fuyuan Investment, and Dr. Fang Xin, managing director of Tii Capital.
Panelists discussed the latest synthetic biology trends, innovative heparin and biomedical applications, emerging opportunities, challenges, and policy suggestions for sustainable industrial growth.
Guangming District has attracted over 130 synthetic biology companies, with an estimated industry value approaching 40 billion yuan. The district has nurtured an innovation ecosystem spanning basic research, technology breakthroughs, commercialization, finance, and talent development. Bloomage Gag's arrival is expected to strengthen the cluster of upstream and downstream enterprises in beauty and cosmetics, boosting Guangming's ambition to build a world-class synthetic biology hub with distinctive scientific advantages.